Wellmarker Bio signs MoU with Isogenica for the development of multiple therapeutic assets

May 30, 2022

The MoU will serve as a foundation for increased cooperation between the two companies

Dr Bill Eldridge, CEO of Isogenica, and Professor Dong-Hoon Jin, CEO of WMBIO, holding the MoU.


Wellmarker Bio (WMBIO) and Isogenica today announced the signing of a Memorandum of Understanding (MoU).

Wellmarker Bio (WMBIO), is a clinical stage biotechnology company developing first-in-class anticancer drugs based on predictive biomarkers for unmet medical needs. Isogenica is a biotechnology company that specialises in the discovery and optimisation of therapeutic and diagnostic peptides, proteins and antibodies using its proprietary technologies.

Under the terms of the MoU, the two companies will collaborate in the research and development of antibody-based cancer immunotherapy, Protein-Protein Interaction (PPI) Inhibitors, biomarkers and peptide 

libraries; with joint funding, including UK or other government grants they will collaborate to create a portfolio of preclinical programs from early target identification through to candidate nomination.

This MoU will serve as a foundation for increased cooperation between the two companies and will leverage their joint strengths to expand into new markets, providing patients with more effective and affordable medicines.

In addition, Isogenica Ltd., a leader in synthetic biology and in vitro discovery and optimisation of novel biotherapeutics, today announced it has entered into a licensing agreement with WMBIO.

The collaboration will combine each company’s expertise and experience in recombinant protein technologies, through the design and construction of highly diverse synthetic libraries and the use of novel in vitro polypeptide display systems. Isogenica will apply its proprietary CIS display technology for the discovery of novel therapeutics to progress Wellmarker Bio’s pipeline in cancer and other indications.

“Isogenica’s collaboration with WMBIO focusing on individualised, effective and affordable therapies for patients with high unmet medical need is an exciting opportunity to accelerate development of novel targeted therapeutics,” said Dr Bill Eldridge, CEO of Isogenica. “Pairing Isogenica’s expertise in synthetic libraries and protein engineering with WMBIO commitment to developing first-in-class anti-cancer drugs based on predictive biomarkers promises to be an efficient and cost-effective means to develop individualised therapies.”

Professor Dong-Hoon Jin, CEO of WMBIO, commented, “Wellmarker Bio is very excited to be collaborating with Isogenica and look forward to developing a host of effective and affordable anticancer drugs based on Isogenica’s platform.”

Further Information

About Isogenica

Isogenica is a peptide and antibody discovery and development company. Isogenica’s CIS Display technology, an in vitro biotherapeutic discovery technology with significant advantages over more traditional techniques in terms of library size and versatility, enables the full diversity of the company’s massive peptide and antibody libraries to be exploited. With this technology, the company has a unique and proven engine for biotherapeutic discovery and development. Working in collaboration with biopharmaceutical partners over the last decade the company has developed a deep pipeline including two clinical stage assets and more than ten partnered pre-clinical and discovery stage programmes.

Further information, visit: www.isogenica.com

About WellMarker Bio

Wellmarker Bio Co., Ltd (WMBIO), the first company to be spun out from the renowned Asan Medical Center, Korea’s largest hospital, focuses on the development of novel anticancer drugs derived from comprehensive biomarker analysis. Since its founding in 2016, WMBIO has developed 9 first-in-class drugs for indications including solid tumors. Having access to a wide array of patient samples from Asia and using predictive biomarkers to guide therapeutic development in innovative ways has allowed WMBIO to rapidly move its assets from exploratory to preclinical and now into early clinical stages. WMBIO’s R&D strategy is to focus mainly on drug discovery and early-stage development of lead compounds to build a deep and wide pipeline of products that could carry up to and through phase 1 clinical trials. Once a drug candidate is at that stage, WMBIO seeks co-development or licensing partners among global pharmaceutical companies or other relevant players.

Further information, visit: www.wmbio.co 


Dave Mead,
Buisness Development, Isogenica

T +44 1799 533 680

E david.mead@isogenica.com

Jai-Hee Moon,
Strategic Planning Manager, Wellmarker Bio

E jhmoon@wmbio.co